217 related articles for article (PubMed ID: 19352084)
1. [Molecular bases of leukemia, MPD and MDS].
Kitamura T
Rinsho Ketsueki; 2009 Mar; 50(3):174-81. PubMed ID: 19352084
[No Abstract] [Full Text] [Related]
2. [Molecular mechanisms in myeloproliferative diseases and myelodysplastic syndromes].
Harada H; Harada Y; Kimura A
Nihon Rinsho; 2009 Oct; 67(10):1901-5. PubMed ID: 19860187
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders.
Kim YK; Shin MG; Kim HR; Yang DH; Cho SH; Lee JJ; Chung IJ; Ryang DW; Kim HJ
Leuk Res; 2008 Jun; 32(6):993-5. PubMed ID: 18055011
[No Abstract] [Full Text] [Related]
4. JAK2-V617F and BCR-ABL--double jeopardy?
Krämer A
Leuk Res; 2008 Oct; 32(10):1489-90. PubMed ID: 18439674
[No Abstract] [Full Text] [Related]
5. Myeloproliferative disorders with coexisting BCR-ABL translocation and JAK2(V617F) mutation.
Go RS
Leukemia; 2007 Sep; 21(9):2051; author reply 2052. PubMed ID: 17597806
[No Abstract] [Full Text] [Related]
6. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features.
Wang SA; Hasserjian RP; Loew JM; Sechman EV; Jones D; Hao S; Liu Q; Zhao W; Mehdi M; Galili N; Woda B; Raza A
Leukemia; 2006 Sep; 20(9):1641-4. PubMed ID: 16871284
[No Abstract] [Full Text] [Related]
7. Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation.
Hussein K; Bock O; Theophile K; Seegers A; Arps H; Basten O; Grips KH; Franz-Werner J; Büsche G; Kreipe H
Leukemia; 2008 May; 22(5):1059-62. PubMed ID: 17972958
[No Abstract] [Full Text] [Related]
8. Concomitant detection of BCR-ABL translocation and JAK2 V617F mutation in five patients with myeloproliferative neoplasm at diagnosis.
Cappetta M; Pérez V; Zubillaga MN; Elizondo V; Manrique G; Prosper I; Boschi S; Bonomi R; Pomoli S; Díaz L; Martínez L; Uriarte MR
Int J Lab Hematol; 2013 Feb; 35(1):e4-5. PubMed ID: 23062104
[No Abstract] [Full Text] [Related]
9. Molecular bases of myelodysplastic syndromes: lessons from animal models.
Komeno Y; Kitaura J; Kitamura T
J Cell Physiol; 2009 Jun; 219(3):529-34. PubMed ID: 19259975
[TBL] [Abstract][Full Text] [Related]
10. The JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis.
Kremer M; Horn T; Dechow T; Tzankov A; Quintanilla-Martínez L; Fend F
Leukemia; 2006 Jul; 20(7):1315-6. PubMed ID: 16617316
[No Abstract] [Full Text] [Related]
11. [Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes].
Bock O
Verh Dtsch Ges Pathol; 2007; 91():140-53. PubMed ID: 18314608
[TBL] [Abstract][Full Text] [Related]
12. Reply to Kremer M et al., the JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis.
Ohyashiki K; Ohyashiki JH
Leukemia; 2006 Jul; 20(7):1297-8. PubMed ID: 16617315
[No Abstract] [Full Text] [Related]
13. The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients.
Ohyashiki K; Aota Y; Akahane D; Gotoh A; Miyazawa K; Kimura Y; Ohyashiki JH
Leukemia; 2005 Dec; 19(12):2359-60. PubMed ID: 16239910
[No Abstract] [Full Text] [Related]
14. Clinicopathological features of unbalanced translocation Der(1;7)(q10;p10) in myeloid neoplasms.
So CC; Ma ES; Wan TS; Yip SF; Chan LC
Leuk Res; 2008 Jun; 32(6):1000-1. PubMed ID: 17980911
[No Abstract] [Full Text] [Related]
15. [Molecular pathogenesis of MDS].
Mitani K
Rinsho Ketsueki; 2009 Oct; 50(10):1325-31. PubMed ID: 19915339
[No Abstract] [Full Text] [Related]
16. Mutations of N-RAS, FLT3 and p53 genes are not involved in the development of acute leukemia transformed from myeloproliferative diseases with JAK2 mutation.
Suzuki M; Abe A; Kiyoi H; Murata M; Ito Y; Shimada K; Morishita Y; Kinoshita T; Naoe T
Leukemia; 2006 Jun; 20(6):1168-9. PubMed ID: 16557239
[No Abstract] [Full Text] [Related]
17. Evolution of secondary hematologic disorders: preMDS-->MDS-->sAML.
Preisler HD
Cancer Treat Res; 2001; 108():185-230. PubMed ID: 11702600
[No Abstract] [Full Text] [Related]
18. [Application of novel tyrosine-kinase inhibitors for the treatment of leukemia and Ph-negative myeloproliferative neoplasms].
Kirito K
Rinsho Ketsueki; 2011 Jul; 52(7):460-8. PubMed ID: 21821977
[No Abstract] [Full Text] [Related]
19. Chronic myeloproliferative neoplasm with concurrent BCR-ABL translocation and JAK2 mutation.
Siddiqui NS; Ssiddiqui HS; Qurat-Ul-Ain ; Siddiqui SA
J Coll Physicians Surg Pak; 2010 Jun; 20(6):423. PubMed ID: 20642980
[No Abstract] [Full Text] [Related]
20. Gain of function, loss of control - a molecular basis for chronic myeloproliferative disorders.
Cazzola M; Skoda R
Haematologica; 2005 Jul; 90(7):871-4. PubMed ID: 15996923
[No Abstract] [Full Text] [Related]
[Next] [New Search]